[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.167.137. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Letters
March 28, 2001

Immunogenicity of Bivalent AC Polysaccharide Meningococcal Vaccine in Children Aged 6 Through 24 Months

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;285(12):1578-1579. doi:10.1001/jama.285.12.1578

To the Editor: In a study of the effectiveness of a mass immunization campaign in Quebec against meningococcal disease, De Wals et al1 recently reported on a lack of clinical protection against invasive meningococcal type C infections in children younger than 2 years who were immunized with the polysaccharide meningococcal vaccine. Because of concerns about the efficacy of the vaccine in children younger than 2 years, we evaluated the immunogenicity of this vaccine in children younger than 2 years during the same immunization campaign.

First Page Preview View Large
First page PDF preview
First page PDF preview
×